This inventor holds 1 USPTO granted patent. Top assignee: Zymogenetics, Inc.. Active years: 1993.
Company Filing History:
Years Active: 1993
Title: Kurt Pingel: Innovator in Fibrinolytic Activity
Introduction
Kurt Pingel is a notable inventor based in Farum, Denmark. He has made significant contributions to the field of medical science, particularly in the development of thrombin-activated tissue plasminogen activators. His work focuses on enhancing fibrinolytic activity, which is crucial for effective blood clot management.
Latest Patents
Kurt Pingel holds a patent for "Thrombin-activated tissue plasminogen activators." This invention discloses zymogens of proteins that exhibit fibrinolytic activity. The proteins are designed to be cleavable by thrombin, leading to the stimulation of fibrinolytic activity. The modified molecules are substantially clot-specific, taking advantage of the large amounts of thrombin associated with clots in vivo. This innovation has the potential to improve therapeutic strategies for clot-related conditions.
Career Highlights
Kurt Pingel is associated with Zymogenetics, Inc., where he has been instrumental in advancing research in fibrinolytic therapies. His expertise and innovative approach have positioned him as a key figure in the field.
Collaborations
Kurt has collaborated with notable colleagues, including Eileen R Mulvihill and Donald C Foster. These partnerships have contributed to the development and refinement of his innovative ideas.
Conclusion
Kurt Pingel's work in thrombin-activated tissue plasminogen activators represents a significant advancement in medical science. His contributions are paving the way for improved treatments in managing blood clots.